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Abstract
Background: The aim of the study was to evaluate the initial effi-
ciency and security of maximal effort cytoreductive surgery in stages 
III and IV of ovarian cancer at a university hospital.
Methods: Thirty-four patients with stage III and IV ovarian carci-
noma underwent surgery between January 2013 and June 2014 in 
the University General Hospital of Castellon (Spain). Patients with 
primary and relapse ovarian cancer were included. The extent of dis-
ease, type of surgical technique, amount of tumor prior to surgery and 
amount of residual disease after surgery were recorded. To quantify 
the efficiency and the security of the procedure, the complete cytore-
duction and the morbidity and the mortality rates were described.
Results: Of the patients 26.4% received neoadjuvant chemotherapy. 
Complete cytoreductive surgery, without evident residual tumor at the 
end of the procedure, was obtained in 79% of patients and optimal cy-
toreductive surgery (CC0-CC1) in 91%. Surgical complications were 
found in 56% of patients and two deaths (6%) occurred attributable to 
surgery. The disease free interval was 15 months.
Conclusions: This study confirms that with experienced multidis-
ciplinary teams and in tertiary referral hospitals, 79% of complete 
cytoreduction surgery in advanced ovarian cancer can be achieved 
but they must be prepared to deal with a high rate of complications.
Keywords: Cytoreductive surgery; Advanced ovarian cancer; Mor-
bidity; Mortality; Ovary; Cancer; Surgery
Introduction
For patients with advanced epithelial ovarian cancer, the 
amount of post surgery residual tumor constitutes the most im-
portant prognostic factor related to survival. The survival rate 
of 5 years reaches almost 50% for patients with a null residual 
tumor after surgery and diminishes to 5% in patients with re-
sidual tumor > 1 - 2 cm [1].
Therefore we can ensure that surgery is considered essential 
for treatment of advanced epithelial ovarian cancer. In general, 
this cytoreduction surgery (CS) is used initially in advanced 
cases of ovarian cancer including stage IV when metastatic le-
sions present at a distance that does not influence survival in 
the short run. This surgery of cytoreduction ought to attempt to 
remove all metastatic and spreading lesions of the ovarian tu-
mor through the abdominal cavity, such that the residual tumor 
should be reduced to zero upon visual inspection. Only when 
we leave a residual tumor of < 1 cm, optimal surgery of cytore-
duction (OSC), does the prognosis of the patient improve [2].
As previously mentioned, survival of advanced ovarian 
cancer in Castellon (Spain) is low [3]. Recently multidiscipli-
nary techniques of abdominal surgery have been adopted as 
part of the CS. This study analyzes the initial results as much 
in terms of safety as well as in effectiveness in the treatment 
of advanced ovarian cancer at a tertiary referral hospital for 
patients with gynecological cancer.
Material and Methods
From January 2013 to June 2014, a total of 34 patients with 
advanced ovarian epithelial cancer have taken part in the Mul-
tidisciplinary Unit of Abdominal Pelvic Oncology Surgery 
(MUAPOS) at the University General Hospital of Castellon 
(Spain); of these patients 22 presented with primary tumors 
and 12 as relapsed. All procedures were carried out by the 
same surgical team.
The World Health Organization Classification was used 
for the histological classification [4]. The histological degree 
was assessed according to the criteria of Day et al [5]. Stag-
ing was determined by the FIGO system [6]. All patients were 
prepared with the normal colon Citrafleet® the day before the 
procedure. Standard antibiotic prophylactics of metronidazol 
1,500 mg EV and gentamicin 240 mg EV were used the day 
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of the procedure as well as a dose of amoxycillin-clavulanic 
2 g EV at 4 h into surgery. In addition, a thromboprophylaxis 
with heparin of low molecular weight at a standard dose was 
administered and was continued during the post operation pe-
riod, and pneumatic compression stockings were put in place 
until the patient was able to walk.
All these procedures were carried out under general anes-
thesia and by means of a laparotomy xifo-pubic incision. The 
index of peritoneal carcinomatosis (IPC) was calculated accord-
ing to Sugarbaker [7]. Surgery by cytoreduction for advanced 
ovarian cancer is composed of multiple procedures during a 
single operation, thus it was divided into several steps during 
which different abdominal pelvic regions were worked on, fol-
lowing the outline proposed by Morrow [8] (Fig. 1).
In the first area, the abdominal pelvic, routine procedures 
in gynecological oncology such as hysterectomies and adnex-
ectomies are carried out, but in a large number of the patients, 
due to a large quantity of tumors found in the pelvis, a resec-
tion is done in bloc of the uterus, ovaries, pelvic peritoneum, 
resection of associated tumor nodules, and of the rectum as part 
of the pelvic CS (radical pelvic peritonectomy). The procedure 
is carried out following the process described by Morrow [8]. 
Briefly, after opening the retroperitoneal spaces, infundibu-
lopelvic ligaments are cut open and the arteries and ovarian 
veins are tied and a bilateral ureterolysis is carried out. The 
incisions are lengthened through the pararectal passage and are 
penetrated in the retrorectal spaces. The upper rectal vessels are 
cut open as low as possible but above the site of the cancer, a 
bilateral ureterolysis is carried out. The incisions are stretched 
Table 1.  Characteristics of the Patients and of the Illness
n = 34
Age 60 (41 - 84)
Tumor
  Primary 22 (65%)
  Recurrence 12 (35%)
  Serous/Papillary-Serous 14 (41%)
  Endometrioid 5 (15%)
  Granular 1 (3%)
  Mullerian 1 (3%)
  Neuroendocrine 1 (3%)
  Mixed 1 (3%)
  Peritoneal 9 (26%)
  Indistinct 2 (6%)
FIGO
  IIIC 18 (53%)
  IV 16 (47%)
ASA
  I 1 (3%)
  II 9 (26%)
  III 23 (68%)
  IV 1 (3%)
IPC operative 12 (2 - 33)
  1 - 10 13 (38%)
  11 - 20 13 (38%)
  20 8 (24%)
  Primary 14 (4 - 33)
  Recurrence 5 (2 - 24)
CEA 2 (1 - 150)
CA199 17 (3 - 67)
CA125 254 (24 - 14,125)
CA153 115 (5 - 1,500)
Ascites (clinically evident) 9 (26%)
Pleural spillage (radiological) 7 (21%)
Intestinal subocclusion 4 (12%)
  Primary 2 (9%)
  Recurrence 2 (17%)
Preoperative laparoscopy 19 (56%)
  IPC 1 - 10 6 (18%)
  IPC 11 - 20 11 (32%)
  IPC +20 2 (6%)
  IPC 1 - 10 accuracy 33%
  IPC +10 accuracy 63%
Quantitative variables: median (range). Nominal variables: count (%).
Figure 1. Graphs reproducing areas described in the process pro-
posed by Morrow [8]. 
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along the pararectal passage and enter into the recto rectal spac-
es. The superior rectal vessels are cut open as low as possible 
but above the site of the cancer, the sigmoid colon is cut open 
with stapler type GIA (Multifire GIA, Auto Suture, Nor-Walk, 
CT). The rectum is mobilized from the sacrum directing the 
dissection towards the pelvic diaphragm and the middle rectal 
arteries are cut open and tied. The inferior mesenteric artery is 
not cut open as normally done, except when it is necessary to 
mobilize the descending colon to achieve a low collateral anas-
tomosis without tension. A retrograde hysterectomy is carried 
out and the rectum is cut open with a stapler type TA (Multifire 
TA Disposable Stapler, Auto Suture), beneath the peritoneal 
reflection at some 10 cm of the anal margin. This procedure 
as described allows for the resection in-bloc of all pelvic mat-
ter. In cases where a complete-terminal anastomosis was car-
ried out, this was done with an end-stapler EEA (Premium Plus 
CEEA 28 to 33 mm, Auto Suture). At the halfway point of the 
operation, efforts are dedicated to the upper abdomen. Thus, in 
zone 3, which corresponds to the right hypochondrium, pro-
cedures such as diaphragmatic peritonectomy, resection of the 
diaphragmatic muscle, glissectomy, cholecystectomy or hepa-
tectomy are performed as is required per the site of the cancer. 
In zone 4, diaphragmatic peritonectomy, diaphragm resections, 
splenectomy with or without distal pancreatectomy are done, 
if the cancerous site requires it. In zone 2 procedures on the 
stomach, gastrocolic ligaments, upper and lower omentum, 
duodenum, ileum and colon are also performed. Finally in zone 
5, attention is focused on the aortocaval and supramesocolic 
lymph nodes and in the resection of macroscopically swollen 
lymph nodes when found.
Complications are classified according to the degrees of Cla-
vien-Dindo [9] and only those with moderate to high severity (II 
and III degrees) are taken into consideration. The patients are re-
leased from the hospital when they are able to tolerate food; they 
recover bladder and intestinal functions, and they are afebrile.
As primary statistical parameters for analysis, the effec-
tiveness parameters are considered (resectability: complete 
peritonectomies and total cytoreduction) and safety (morbidity 
and mortality).
Quantitative variables are described by the mean ± stand-
ard deviation, or with the median (range) according to the out-
comes. Qualitative variables are characterized by count and 
percentage. The proof of Mann-Whitney, the exact proof as 
Fisher, is used for the univariate analysis, and the simple lineal 
regression, according to the type of variables. For calculations 
of rates of survival, Kaplan-Meier’s method is used. In order 
to calculate free of cancer survival rates a recurrence is consid-
ered when the tumor reappears again in the imaging tests along 
with tumoral markers.
Results
Analysis is based on the results obtained from 34 patients. 
The main characteristics of these patients are shown in Table 
1. Neoadjuvant was administered in primary tumors in nine 
patients (26%). Variables related to the treatment and results 
are summarized in Table 2. The associated visceral resections 
Table 2.  Treatment and Results
n = 34
Visceral resections 30 (88%)
Visceral resections per patient
  0 5 (15%)
  1 1 (3%)
  2 9 (26%)
  3 5 (15%)
  4 3 (9%)
  5 2 (6%)
  7 5 (15%) visceral resections
  8 2 (6%)
  11 1 (3%)
  14 1 (3%)
Peritonectomy (all)
  Complete 21 (62%)
  Partial 7 (21%)
  No 6 (17%)
  Primary
    Complete 18 (82%)
    Partial 3 (14%)
    No 1 (4%)
  Relapse
    Complete 3 (25%)
    Partial 4 (33%)
    No 5 (42%)
Duration of surgery (min) 540 (280 - 750)
  Primary 540 (390 - 750)
  Relapse 480 (280 - 720)
Regulated lymphadenectomies 27 (80%)
  Lymph nodes analyzed 26 (1 - 88)
  Lymph nodes positive 2 (0 - 36)
Infrarenal aorta caval 
lymphadenectomy
27 (80%)
  Lymph nodes analyzed 12 (1 - 28)
  Lymph nodes positive 1 (0 - 12)
Left iliac pelvic lymphadenectomy 23 (66%)
  Lymph nodes analyzed 7 (1 - 29)
  Lymph nodes positive 1 (0 - 11)
Right iliac pelvic 
lymphadenectomy
22 (65%)
  Lymph nodes analyzed 7 (1 - 19)
  Lymph nodes positive 1 (0 - 15)
Supsramesocolic lymphadenectomy 5 (15%)
  Lymph nodes analyzed 2 (1 - 9)
  Lymph nodes positive 1 (0 - 2)
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are shown in Table 3.
All the digestive fistulas corresponded to the leakage of 
colorectal anastomosis. The re-operations correspond to the 
three fistulas and to three eviscerations. Deaths correspond to 
liver failure and to secondary sepsis to necrotizing fasciitis of 
the abdominal wall.
Those who suffer postoperative complications of grade II/
III are of Clavien-Dindo 19 (56%) cases. The most frequent 
were of a septic type: a pleural and pulmonary type, abdominal 
collections, and those related to the incision. Complications 
are associated with major or minor extension of the surgery; 
nonetheless, they are not associated with the presence of co-
morbidity (P = 0.886) nor with age (P = 0.846).
In this way, the average IPC in complicated cases is from 
16 ± 8 against 10 ± 8 in those without complications (P = 
0.026). A major number of complications per patient also are 
associated with the IPC (P = 0.018). Moreover, in complicated 
cases, there is an average of removed viscera of 5 ± 3, while 
in non-complicated cases, there is an average of 2 ± 2. A large 
number of complications per patient are also associated with 
the number of removed viscera (P = 0.001).
Medium follow-up is 7 months (interquartile range: 3.7 
- 10.2). Medium general survival is 16 months, while the me-
dium survival rate free of cancer is 15 months. As can be ob-
served (Fig. 2), relapses begin to appear after 6 months. Even 
though no significant statistical differences (log-rank: P = 
0.663) are found in the event of relapses, it is useful to com-
pare cases with CCO and non-CCO; possibly due to the short 
follow-up time period, the medium survival rate free of ill-
ness was almost double when CCO is compared to non-CCO 
(15 months versus 8 months). No patient received HIPEC. In 
22 (65%) cases postoperative chemotherapy was administered 
with a medium delay of 2 months (0.4 - 8).
Discussion
The Multidisciplinary Unit of Abdominal Pelvic Oncology 
Surgery (MUAPOS) was created at our institution in January 
2013, dedicating itself entirely to the treatment of advanced 
ovarian cancer by incorporating extensive surgical techniques 
for cytoreduction of advanced ovarian and peritoneal cancers. 
This multidisciplinary focus of the technique used has reached 
an improvement in the percentage of optimal achieved cytore-
duction. Thus, in our retrospective series of 34 patients for 
whom a CS for advanced ovarian cancer was performed, we 
statistically analyzed the results obtained in terms of effective-
Table 3.  Visceral Resections in Order of Frequency
Organ n %
Sigmoid colon 18 53
Small intestine 14 41
Cecum and appendiz 13 38
Gallbladder 12 35
Rectum 11 32
Spleen 11 32
Transverse colon 7 21
Ascending colon 5 15
Pancreas body-tail 5 15
Hepatic peritoneum 5 15
Partial bladder 4 12
Descending colon 4 12
Liver 4 12
Diaphragm 4 12
Total bladder 3 9
Ureter 3 9
Major vessels 3 9
Stomach 2 6
Kidney 2 6
Adrenal 2 6
Total 30 cases 88%
n = 34
Cytoreduction
  CC0 27 (79%)
  CC1 4 (12%)
  CC2 2 (6%)
  CC3 1 (3%)
Cytoreducion CC0
  Primary 19 (70%)
  Relapse 8 (30%)
Cytoreduction CC1
  Primary 2 (50%)
  Relapse 2 (50%)
Cytoreduction CC2
  Primary 2 (100%)
  Relapse 0
Cytoreduction CC3
  Primary 0
  Relapse 1 (100%)
Complications 19 (56%)
Digestive fistulas 3 (9%)
Reoperation 6 (18%)
Death 90 days 2 (6%)
Stay in ICU 6 (2 - 36)
Postoperative stay 22 (8 - 63)
  Stay > 20 days 20 (59%)
  Primary 27 (10 - 56)
  Relapse 14 (8 - 63)
Quantitative variables: median (range). Nominal variables: count (%).
Table 2.  Treatment and Results - (Continued)
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ness as well as complications due to the surgery.
Optimal cytoreduction at the time of the first surgery has 
shown to be the most important prognostic factor related to 
the increase in survival of patients with epithelial cancer of 
the ovary [10, 11]. In our retrospective series of patients with 
elevated tumor amounts and stages III and IV of the disease, 
a complete cytoreduction (CC0) was achieved in 79% of the 
cases and an optimal cytoreduction (CC0 or CC1) in 91% of 
the cases. The mean operating IPC was 12 (2 - 33), being in 
62% of the cases above 10. These numbers demonstrate, just 
as it happens in other works, that optimal cytoreduction can 
achieve a high percentage rate in cases even though the tumor 
amount may be high and even though they may be found at 
stage IV of the disease [10, 12]. Some studies have shown that 
centers with an optimal cytoreduction rate > 75% provide a 
50% mean survival rate compared to centers that only offer a 
25% optimal cytoreduction rate. Nevertheless, it is also known 
that an optimal cytoreduction above 50% requires the incor-
poration of extensive surgical techniques in the superior abdo-
men and can require numerous visceral resections [10, 13]. In 
our series visceral resections were carried out in 30 patients 
(88%), the sigmoid colon forming part of the pelvic peritonec-
tomy being the most frequent.
The percentage of patients with neoadjuvant in primary 
tumors was 26.4%. We agree with some other investigators 
that the effect of the fibrosis on the tumor after having admin-
istered chemotherapy can make interval surgery more difficult 
and even could hide areas affected by the tumor [14]. Moreo-
ver, some authors have demonstrated that the best survival and 
the best interval free of the disease is obtained when an optimal 
primary CS is carried out and that each chemotherapy cycle 
added before surgery reduces the percentage of survival [15].
Regulated pelvic and aortic lymphadenectomy in cases of 
advanced ovarian cancer reveal a high affectation of the lymph 
nodes, approximately 40-78%, and this affectation can be of 
a microscopic type in 35% of cases [16, 17]. In our series a 
Figure 2. Curves of survival at the follow-up year (Kaplan-Meier). 
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regulated lymphadenectomy was carried out in 27 cases (80%) 
finding a mean of affected lymph nodes of (0 - 36). Only in 
cases without lymph node affectation, neither deaths nor re-
lapses occurred amongst our patients, and even though there 
was no statistical significance due to the scarce number of cas-
es and follow-up time, the tendency in the series seems evident 
to us. Nevertheless, one will have to await the conclusion of 
the German study LION in order to know the real role of lym-
phadenectomy in advanced ovarian cancer.
Our results reflect 56% of moderate/severe complications 
according to the classification of Clavien-Dindo and a 6% 
mortality rate, similar to other published series [18]. The in-
troduction of extensive surgery within our center required the 
creation of a multidisciplinary team composed by surgeon spe-
cialists from different medical fields (general surgery, vascular, 
gynecologic oncology and urology), who have abundant expe-
rience in their respective areas, but lack knowledge in terms of 
cooperative approach to advanced ovarian cancer. This lack of 
experience could be the reason for the high complication rate 
that the group exposes; however, it should improve over time.
Nonetheless, in our results, contrary to what happens in 
other series [19], associated comorbidity and age are not as-
sociated with a large number of complications. On the other 
hand, as would seem logical, high morbidity is associated with 
high surgical aggressiveness. This is demonstrated by the larg-
er number of complications associated with a higher measure 
of the tumor (ICP > 10). Such cases require more surgical ef-
fort in order to achieve a CCO and, for the same reason, more 
than two viscera dried up in the same patient.
Kuhn et al [13] analyze the influence of extensive surgery 
in the superior abdominal region as part of the CC of advanced 
ovarian cancer and they reach the conclusion that mortality and 
morbidity increased in patients on whom extensive superior 
abdominal surgery had been performed, including procedures 
such as cholecystectomy, splenectomy, distal pancreatectomy, 
diaphragmatic surgery, hepatectomies, etc. As a result, the au-
thors question the risk/benefit of this type of surgery. Never-
theless they also observe that patients who have had superior 
abdominal surgery in which a microscopic residual tumor was 
removed lived a mean of 71 months compared to a 15-month 
mean for those who lived with a residual macroscopic tumor.
Eisenkop [20] demonstrates that there does not exist a con-
crete location of the tumor or a specific surgical maneuver that 
correlates to the biological aggressiveness of the tumor, and 
that, therefore, a cytoreduction procedure should not be modi-
fied nor finalized simply because it affects a specific organ or 
area. Furthermore, nowadays the fact is no longer questioned 
that in terms of survival a surgery of suboptimal cytoreduction 
will not benefit affected patients with advanced ovarian cancer 
[15, 21]. The extent of surgery in patients with advanced ovari-
an cancer should thus be determined by the performance status 
and the capacity of the patient to tolerate this very aggressive 
surgery, as well as by the capacity of a competent surgical team 
to carry it out with diligence, more than by reason of ages, 
location, or extent of the illness present at the time of surgery. 
In spite of the short follow-up time period in these patients, 
the results obtained are in line with other published studies, 
and although some results may not be statistically significant, 
upon comparing complete cytoreduction surgeries with those 
that were not, a tendency is found towards a gained benefit in 
terms of intervals free of disease, as has been the case in stud-
ies previously cited [22].
In conclusion, this study has shown how CS from ad-
vanced ovarian cancer results to be aggressive and complex 
if we want to obtain a CCO; for this reason, specialist teams 
should be prepared to cope with a high rate of complications, 
at least during their initial stages. Through the adequate pro-
cess of patient selection and the acquisition of a greater experi-
ence in the cooperative treatment of advanced ovarian cancer, 
overall results for this type of surgery should experience a 
rapid increase, in terms of efficiency and safety.
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